Lead Sponsor

Ferring Pharmaceuticals

Age

18 - 44 years

Sex

FEMALE

Healthy Volunteers

No

•Delivered at the hospital system associated with the trial center
•Delivered preterm singleton gestational age 24 weeks + 0 days to 34 weeks + 2 days
•Willing to express milk at least 5 times every 24 hours during the observation period and 6 to 8 times every 24 hours during the treatment and post-treatment follow up
•Produced \< 200 mL milk in 24 hours prior to randomization
•Delivered 96 to 192 (+4) hours prior to randomization

•Pre-pregnancy body mass index (BMI) \> 50 kg/m\^2
•Mastitis
•History of breast trauma, breast surgery, nipple piercing
•Prolactin-releasing pituitary tumor, history of Sheehan's syndrome, pituitary surgery/radiation therapy
•Pre-pregnancy insulin-dependent diabetes mellitus, polycystic ovarian syndrome. Note: gestational diabetes is allowed (also when requiring the use of insulin for treatment)
•Unstable thyroid disease
•Moderate or severe renal or hepatic impairment
•Mental illness
•Significant nasal congestion or mucous production
•Use of anti-psychotic drugs within past 12 months

Related studies

NCT05966649 · Preterm Spontaneous Labor With Preterm Delivery, Preterm Birth, and more

NCT05430321 · Preterm Labor, Preterm Labor With Preterm Delivery in Third Trimester, and more

NCT03596125 · Preterm Delivery

NCT04301388 · Preterm Delivery Within 7 Day After Admission

NCT04110704 · Preterm Birth, Preterm Premature Rupture of Membrane, and more

Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely